Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Molecules ; 25(24)2020 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-33352999

RESUMEN

Ionic liquids are potential alternative electrolytes to the more conventional solid-state options under investigation for future energy storage solutions. This review addresses the utilization of IL electrolytes in energy storage devices, particularly pyrrolidinium-based ILs. These ILs offer favorable properties, such as high ionic conductivity and the potential for high power drain, low volatility and wide electrochemical stability windows (ESW). The cation/anion combination utilized significantly influences their physical and electrochemical properties, therefore a thorough discussion of different combinations is outlined. Compatibility with a wide array of cathode and anode materials such as LFP, V2O5, Ge and Sn is exhibited, whereby thin-films and nanostructured materials are investigated for micro energy applications. Polymer gel electrolytes suitable for layer-by-layer fabrication are discussed for the various pyrrolidinium cations, and their compatibility with electrode materials assessed. Recent advancements regarding the modification of typical cations such a 1-butyl-1-methylpyrrolidinium, to produce ether-functionalized or symmetrical cations is discussed.


Asunto(s)
Suministros de Energía Eléctrica , Líquidos Iónicos/química , Litio/química , Pirrolidinas/química , Electrólitos
2.
Clin Cancer Res ; 28(11): 2297-2305, 2022 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-35247922

RESUMEN

PURPOSE: Ramucirumab is an effective treatment for patients with advanced hepatocellular carcinoma (aHCC) and baseline alpha-fetoprotein (AFP) ≥400 ng/mL. We aimed to identify prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP ≥400 ng/mL from the phase III REACH and REACH-2 randomized trials. PATIENTS AND METHODS: Patients with aHCC, Child-Pugh class A with prior sorafenib treatment were randomized in REACH and REACH-2 (ramucirumab 8 mg/kg or placebo, biweekly). Meta-analysis of individual patient-level data (pooled population) from REACH (AFP ≥400 ng/mL) and REACH-2 was performed. A drug exposure analysis was conducted for those with evaluable pharmacokinetic data. To identify potential prognostic factors for overall survival (OS), multivariate analyses were performed using a Cox proportional hazards regression model. To define predictors of ramucirumab benefit, subgroup-by-treatment interaction terms were evaluated. RESULTS: Of 542 patients (316 ramucirumab, 226 placebo) analyzed, eight variables had independent prognostic value associated with poor outcome (geographical region, Eastern Cooperative Oncology Group performance score ≥1, AFP >1,000 ng/mL, Child-Pugh >A5, extrahepatic spread, high neutrophil-to-lymphocyte ratio, high alkaline phosphatase and aspartate aminotransferase). Ramucirumab survival benefit was present across all subgroups, including patients with very aggressive HCC [above median AFP; HR: 0.64; 95% confidence interval (CI): 0.49-0.84] and nonviral aHCC (HR: 0.56; 95% CI: 0.40-0.79). While no baseline factor was predictive of a differential OS benefit with ramucirumab, analyses demonstrated an association between high drug exposure, treatment-emergent hypertension (grade ≥3), and increased ramucirumab benefit. CONCLUSIONS: Ramucirumab provided a survival benefit irrespective of baseline prognostic covariates, and this benefit was greatest in patients with high ramucirumab drug exposure and/or those with treatment-related hypertension.


Asunto(s)
Carcinoma Hepatocelular , Hipertensión , Neoplasias Hepáticas , Anticuerpos Monoclonales Humanizados , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Ensayos Clínicos Fase III como Asunto , Humanos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , alfa-Fetoproteínas , Ramucirumab
3.
ChemistryOpen ; 8(12): 1429-1436, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31867151

RESUMEN

Thermally stable, flexible polymer gel electrolytes with high ionic conductivity are prepared by mixing the ionic liquid 1-butyl-1-methylpyrrolidinium bis(trifluoromethylsulfonyl)imide (C4mpyrTFSI), LiTFSI and poly(vinylidene difluoride-co-hexafluoropropylene (PVDF-HFP). FT-IR and Raman spectroscopy show that an amorphous film is obtained for high (60 %) C4mpyrTFSI contents. Thermogravimetric analysis (TGA) confirms that the polymer gels are stable below ∼300 °C in both nitrogen and air environments. Ionic conductivity of 1.9×10-3 S cm-2 at room temperature is achieved for the 60 % ionic liquid loaded gel. Germanium (Ge) anodes maintain a coulombic efficiency above 95 % after 90 cycles in potential cycling tests with the 60 % C4mpyrTFSI polymer gel.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA